Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Update

Protara Therapeutics, Inc. (NASDAQ:TARA) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 2,970,000 shares, a decline of 28.4% from the February 13th total of 4,150,000 shares. Based on an average trading volume of 2,310,000 shares, the short-interest ratio is presently 1.3 days. Approximately 16.5% of the shares of the stock are short sold.

Protara Therapeutics Price Performance

TARA traded up $0.29 during trading on Friday, hitting $4.31. The company had a trading volume of 150,726 shares, compared to its average volume of 303,764. The company has a market cap of $88.92 million, a PE ratio of -1.53 and a beta of 1.69. The business has a 50-day moving average of $4.42 and a 200-day moving average of $3.48. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.09. Research analysts forecast that Protara Therapeutics will post -3.32 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

A number of large investors have recently modified their holdings of TARA. XTX Topco Ltd acquired a new position in shares of Protara Therapeutics in the 3rd quarter worth approximately $60,000. Geode Capital Management LLC boosted its holdings in shares of Protara Therapeutics by 21.0% in the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after buying an additional 29,514 shares during the period. Bailard Inc. acquired a new position in shares of Protara Therapeutics in the fourth quarter worth about $157,000. Oppenheimer & Co. Inc. boosted its holdings in shares of Protara Therapeutics by 12.4% during the fourth quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company’s stock worth $1,064,000 after purchasing an additional 22,301 shares during the period. Finally, RA Capital Management L.P. boosted its holdings in shares of Protara Therapeutics by 78.9% during the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock worth $17,952,000 after purchasing an additional 1,500,000 shares during the period. Institutional investors and hedge funds own 38.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Thursday, March 6th. Guggenheim restated a “buy” rating and issued a $20.00 target price on shares of Protara Therapeutics in a report on Friday, December 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a research note on Friday. They set an “overweight” rating for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.